Zhou PY, Zhu DX, Chen YJ, Feng QY, Mao YH, Zhuang AB, Xu JM. High patatin like phospholipase domain containing 8 expression as a biomarker for poor prognosis of colorectal cancer. World J Gastrointest Oncol 2024; 16(3): 787-797 [PMID: 38577466 DOI: 10.4251/wjgo.v16.i3.787]
Corresponding Author of This Article
Jian-Min Xu, PhD, Professor, Surgeon, Department of General Surgery, Zhongshan Hospital Fudan University, No. 180 Fenglin Road, Shanghai 200032, China. xujmin@aliyun.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Peng-Yang Zhou, De-Xiang Zhu, Yi-Jiao Chen, Qing-Yang Feng, Yi-Hao Mao, Ao-Bo Zhuang, Jian-Min Xu, Department of General Surgery, Zhongshan Hospital Fudan University, Shanghai 200032, China
Author contributions: Zhou PY carried out the studies; Zhuang AB and Chen YJ participated in collecting data and drafted the manuscript; Mao YH and Feng QY performed statistical analysis and participated in its design; Zhu DX participated in acquisition, analysis, and interpretation of data and drafted the manuscript; all authors read and approved the final manuscript.
Institutional review board statement: This study was approved by the Clinical Research Ethics Committee of Zhongshan Hospital, Fudan University.
Informed consent statement: Informed consent was acquired from all patients of the primary cohort for the acquisition of clinical and pathological information and the use of surgical specimens.
Conflict-of-interest statement: The authors report having no relevant conflicts of interest for this article.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jian-Min Xu, PhD, Professor, Surgeon, Department of General Surgery, Zhongshan Hospital Fudan University, No. 180 Fenglin Road, Shanghai 200032, China. xujmin@aliyun.com
Received: August 22, 2023 Peer-review started: August 22, 2023 First decision: November 21, 2023 Revised: December 19, 2023 Accepted: January 22, 2024 Article in press: January 22, 2024 Published online: March 15, 2024 Processing time: 203 Days and 2.7 Hours
ARTICLE HIGHLIGHTS
Research background
The role of patatin like phospholipase domain containing 8 (PNPLA8) in colorectal cancer (CRC) progression is unclear.
Research motivation
The research motivation is to explore the prognostic effects of PNPLA8 expression in CRC.
Research objectives
To evaluate the prognostic value of PNPLA8 expression level for CRC patient survival and its correlation with clinicopathological features of CRC patients.
Research methods
PNPLA8 expression in tumor samples was evaluated by immunohistochemistry staining and semi-quantitated with immunoreactive scores.
Research results
CRC patients with high PNPLA8 expression indicated poor overall survival (OS) (median OS = 35.3, P = 0.005). The multivariate analysis also confirmed that high PNPLA8 expression was a significantly independent prognostic factor for overall survival (hazard ratio HR = 1.328, 95%CI: 1.016-1.734, P = 0.038).
Research conclusions
High PNPLA8 expression level is associated with poorer survival outcomes in CRC patients, indicating its prognostic value for predicting patient outcomes.
Research perspectives
Further studies are needed to validate the prognostic value of PNPLA8 in multicenter cohorts of CRC patients. The mechanism of PNPLA8 in CRC development and progression remains to be fully investigated to help to identify potential therapeutic targets and develop new treatment strategies.
